263P Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data von Rached, L.W., Spotti, M.P., Baldini, C., Laparra, A., Dutertre Remote, C.A., Sakkal, M., Perret, A., Viansone, A.A., Zeghondy, J.Z., Rassy, E., Bousrih, C., Abdayem, P., Khoury Abboud, R.M., El Masri, H.K., Grinda, T., Terencio, S. Moragon, Verret, B., Champiat, S., Pistilli, B., Ribeiro, J.T.M.L.

Volltext

57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients von Tolosa Ortega, P., Cejalvo, J.M., Moragon Terencio, S., Carril-Ajuria, L., Bermejo, B., Ruiz, Á., Hernando Melia, C., Sánchez-Torre, A., Martínez, M.T., Herrera, M., Gambardella, V., Lema, L., Roda, D., Bernal, E., Rentero-Garrido, P., Lluch, A., Ciruelos, E.M., Cervantes, A., Manso, L.

Volltext